Compare AT&T Inc. (T) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AT&T Inc. vs GeneDx Holdings Corp — how do they compare? AT&T Inc. trades at $25.22 (market cap $172.34B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: AT&T Inc. is far larger — about 66.8× GeneDx Holdings Corp's market cap, and AT&T Inc. pays a 4.41% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| T | WGS | |
|---|---|---|
Market Cap | $172.34B | $2.58B |
Sector | Media | Technology |
52-Week High | $29.62 | $167.51 |
52-Week Low | $20.49 | $34.51 |
Enterprise Value | $317.66B | $2.61B |
Dividend Yield | 4.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $25.61, down 0.21% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 8.45, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent developments include strategic partnerships with Amazon for satellite broadband and continued fiber expansion, positioning the company for growth in the competitive telecom sector.
The outlook for AT&T remains positive with analyst consensus pointing to 8% upside to the $27.69 price target. Key opportunities include fiber infrastructure expansion and wireless network enhancements, while risks involve heavy capital expenditures and competitive pressures. The stock offers value with attractive valuation metrics and dividend yield, supported by improving cash flow trends and debt reduction efforts.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
